Human cytomegalovirus (HCMV) infection is an important clinical problem for patients undergoing allogeneic transplantation. The most important manifestation of infection is interstitial pneumonitis, an often fatal complication occurring during the first 100 days after transplantation. Although the pathogenesis of infection is not understood, there is substantial evidence from both murine and human studies to indicate that the disease may be mediated immunologically rather than by direct viral damage. We hypothesize that the interstitial pneumonitis associated with HCMV in the allogeneic setting is an immunopathologic process that is mediated by cytokines, e.g., TNF-alpha, TNF-beta, IL-1, IL-2 and interferon-gamma. HCMV in this setting leads to stimulation of immune cells of the lung which induces local production of cytokines which mediate tissue injury. In this proposal, we will investigate the role of these cytokines in the tissue injury of the lungs of mice during interstitial pneumonitis associated with HCMV infection and GVHD and in patients with HCMV infection of the lung before and during the course of interstitial pneumonitis. This will be accomplished by direct measurements of specific cytokines from blood and cells obtained by bronchoalveolar lavage and by molecular methods to assess production of these cytokines. In the murine model we will determine the effect of monoclonal or polyclonal antibody to these cytokines on the course of pneumonitis. Finally, we will also examine the effect of HCMV and MCMV on cytokine secretion and whether these cytokines alter the cellular susceptibility to infection by HCMV or MCMV. These investigations should allow us to determine the role of cytokines in the pathophysiology of pneumonitis following allogeneic transplantation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA030206-11
Application #
3794469
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
1992
Total Cost
Indirect Cost
Name
City of Hope National Medical Center
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications